Does Eptifibatide work?
Yes, in large controlled trials. The main trial had 10,948 people.
The acute coronary syndrome indication rests on PURSUIT, a randomized, double-blind, placebo-controlled trial of 10,948 patients, with supporting trials in PCI (IMPACT-II, ESPRIT) summarized in the label. The absolute benefit is small, about 1.5 percentage points fewer deaths or heart attacks at 30 days, and comes at the cost of more bleeding. 23
PURSUIT randomized 10,948 patients with unstable angina or non-ST-elevation heart attack. They got eptifibatide or placebo for up to 72 hours, along with aspirin and heparin. At 30 days, death or heart attack had hit 14.2% of eptifibatide patients and 15.7% of placebo patients. That is an absolute drop of 1.5 percentage points. It was statistically significant. It was already clear at 96 hours. Most of the benefit went to patients who then had a coronary intervention. 2
Bleeding was the trade-off. Major bleeding and red-cell transfusions were more frequent on eptifibatide. Hemorrhagic stroke was not. Later PCI trials in the label confirmed fewer ischemic problems around stent procedures. That is where doctors mostly use the drug today. Oral antiplatelet drugs have cut its role in patients managed with medicine alone. 23
Evidence checklist
- Randomised controlled trial PURSUIT placebo-controlled trial
- Human study over 100 people PURSUIT, 10,948 patients
- More than one research group PURSUIT plus IMPACT-II and ESPRIT
- Clinical outcomes, not surrogate markers Death or heart attack at 30 days
- Human safety data beyond case reports Bleeding and platelet drop documented in label
Read the full Eptifibatide page
More on Eptifibatide
Citations
- Scarborough 1991, Journal of Biological Chemistry: barbourin, a GPIIb-IIIa-specific integrin antagonist from pygmy rattlesnake venom pubmed.ncbi.nlm.nih.gov
- PURSUIT Trial Investigators 1998, NEJM: inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in acute coronary syndromes doi.org
- Merck: Integrilin (eptifibatide) prescribing information merck.com
Reference information only, not medical advice. Drawn from the Eptifibatide article, fact-checked against the cited sources. No dosing anywhere on this site.